A Probiotic Strain Dedicated to Babies
B.infantis Rosell®-33 has been studied in a randomized, double-blind, placebo-controlled study [Manzano, 2017], confirming its safety and tolerance in 221 healthy three to twelve month-old infants. The post-hoc analysis [De Andres, 2018] based on a sample of infants from the Manzano 2017 study, showed the following beneficial effects of B. infantis Rosell®-33:
- Maintenance of a baby-specific microbiome profile rich in bacteria able to digest lactose such as Bifidobacteria, regardless of any influencing factors (diets, birth mode, etc.). By opposition, in the placebo group, there were a significant increase in common constituents of healthy adult gut microbiota, and a decrease of Bifidobacteria (most specifically bifidum and B. breve)
- Increase of the anti-inflammatory IL-10/IL-12 ratio during the 8-week period of intake whereas placebo turns towards a pro-inflammatory state
B. infantis Rosell®33 is also included in Probiokid® formula, gathering 28 clinical studies performed in infants and children
A good synergy with human milk oligosaccharides (HMO)
The most abundant HMO in human breast milk, representing 30% of all HMOs, is 2’-FL (2’-Fucosyllactose). An in vitro test showed that B. infantis Rosell®-33 was able to metabolize HMOs.
Proven as safe
B.infantis Rosell®-33 can be formulated in sachets and drops, and it can also be added in infant formulas. The strain is GRAS in the US for use in infant formulas from birth and is also authorized for use in infant food in China.